ThermoGenesis (THMO) 10-Q 19 May 22 2022 Q1 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	3 Months Ended
	Mar. 31, 2022	May 18, 2022
Document Information [Line Items]
Entity Central Index Key	0000811212
Entity Registrant Name	ThermoGenesis Holdings, Inc.
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Document Fiscal Period Focus	Q1
Document Fiscal Year Focus	2022
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Mar. 31, 2022
Document Transition Report	false
Entity File Number	333-82900
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	94-3018487
Entity Address, Address Line One	2711 Citrus Road
Entity Address, City or Town	Rancho Cordova
Entity Address, State or Province	CA
Entity Address, Postal Zip Code	95742
City Area Code	916
Local Phone Number	858-5100
Security Exchange Name	NASDAQ
Title of 12(b) Security	Common Stock, $.001 par value
Trading Symbol	THMO
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		12,829,877

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets (Current Period Unaudited) - USD ($)	Mar. 31, 2022	Dec. 31, 2021
Current assets:
Cash and cash equivalents	$ 3,652,000	$ 7,280,000
Accounts receivable, net of allowance for doubtful accounts of $156,000 at March 31, 2022 and December 31, 2021	2,175,000	733,000
Inventories	5,893,000	5,373,000
Prepaid expenses and other current assets	1,474,000	1,578,000
Total current assets	13,194,000	14,964,000
Inventories non-current, net	1,197,000	1,709,000
Equipment and leasehold improvements, net	1,224,000	1,261,000
Right-of-use operating lease assets, net	525,000	571,000
Goodwill	781,000	781,000
Other intangible assets, net	1,310,000	1,318,000
Other assets	48,000	48,000
Total assets	18,279,000	20,652,000
Current liabilities:
Accounts payable	1,866,000	1,280,000
Accrued payroll and related expenses	456,000	348,000
Deferred revenue – short-term	1,159,000	719,000
Notes Payable, Related Parties, Current	10,000,000
Interest payable – related party	153,000	2,231,000
Convertible promissory note, net	1,000,000	813,000
Other current liabilities	843,000	957,000
Total current liabilities	15,477,000	6,348,000
Convertible promissory note – related party, net		9,245,000
Operating lease obligations – long-term	338,000	398,000
Deferred revenue – long-term	1,163,000	1,244,000
Other noncurrent liabilities	19,000	20,000
Total liabilities	16,997,000	17,255,000
Commitments and contingencies
Stockholders’ equity:
Preferred stock, $0.001 par value; 2,000,000 shares authorized, none outstanding	0	0
Common stock, $0.001 par value; 350,000,000 shares authorized; 12,829,877 issued and outstanding (11,911,784 at December 31, 2021)	13,000	12,000
Additional paid in capital	258,614,000	268,447,000
Accumulated deficit	(256,833,000)	(264,662,000)
Accumulated other comprehensive loss	45,000	31,000
Total ThermoGenesis Holdings, Inc. stockholders’ equity	1,839,000	3,828,000
Noncontrolling interests	(557,000)	(431,000)
Total equity	1,282,000	3,397,000
Total liabilities and equity	$ 18,279,000	$ 20,652,000

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) - USD ($)	Mar. 31, 2022	Dec. 31, 2021
Accounts receivable, allowance for doubtful accounts	$ 156,000	$ 156,000
Preferred stock, par value (in dollars per share)	$ 0.001	$ 0.001
Preferred stock, shares authorized (in shares)	2,000,000	2,000,000
Preferred stock, shares outstanding (in shares)	0	0
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized (in shares)	350,000,000	350,000,000
Common stock, shares issued (in shares)	12,829,877	11,911,784
Common stock, shares outstanding (in shares)	12,829,877	11,911,784

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Net revenues	$ 2,663,000	$ 1,517,000
Cost of revenues	1,723,000	809,000
Gross profit	940,000	708,000
Expenses:
Selling, general and administrative	1,693,000	1,992,000
Research and development	456,000	379,000
Total operating expenses	2,149,000	2,371,000
Loss from operations	(1,209,000)	(1,663,000)
Other income (expenses):
Interest expense	(823,000)	(1,519,000)
Other income (expenses)	(4,000)	(1,000)
Gain on extinguishment of debt		(652,000)
Total other expenses	(827,000)	(868,000)
Net loss	(2,036,000)	(2,531,000)
Loss attributable to noncontrolling interests	(126,000)	(118,000)
Net loss attributable to common stockholders	(1,910,000)	(2,413,000)
Net loss	(2,036,000)	(2,531,000)
Other comprehensive loss:
Foreign currency translation adjustments gain (loss)	14,000	1,000
Comprehensive loss	(2,022,000)	(2,530,000)
Comprehensive loss attributable to noncontrolling interests	(126,000)	(118,000)
Comprehensive loss attributable to common stockholders	$ (1,896,000)	$ (2,412,000)
Per share data:
Basic and diluted net loss per common share (in dollars per share)	$ (0.16)	$ (0.21)
Weighted average common shares outstanding basic and diluted (in shares)	12,288,517	11,446,366

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Equity (Unaudited) - USD ($)	At The Market Offering Agreement [Member]Common Stock [Member]	At The Market Offering Agreement [Member]Additional Paid-in Capital [Member]	At The Market Offering Agreement [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	AOCI Attributable to Parent [Member]	[1]	Noncontrolling Interest [Member]	Total
Balance (in shares) at Dec. 31, 2020				8,934,952
Balance at Dec. 31, 2020				$ 9,000	$ 259,058,000	$ (253,283,000)	$ 16,000		$ 70,000	$ 5,870,000
Stock-based compensation expense					258,000					258,000
Issuance of common stock via at-the-market offering, net (in shares)				2,976,832
Issuance of common stock via at-the-market offering, net				$ 3,000	6,829,000					6,832,000
Foreign currency translation gain (loss)							1,000			1,000
Net loss						(2,413,000)			(118,000)	(2,531,000)
Balance (in shares) at Mar. 31, 2021				11,911,784
Balance at Mar. 31, 2021				$ 12,000	266,145,000	(255,696,000)	17,000		(48,000)	10,430,000
Balance (in shares) at Dec. 31, 2021				11,911,784
Balance at Dec. 31, 2021				$ 12,000	268,447,000	(264,662,000)	31,000		(431,000)	3,397,000
Adoption of ASU 2020-06					(10,681,000)	9,739,000				(942,000)
Stock-based compensation expense					42,000					42,000
Issuance of common stock via at-the-market offering, net (in shares)	918,093
Issuance of common stock via at-the-market offering, net	$ 1,000	$ 593,000	$ 594,000
Related party convertible note price reset					213,000					213,000
Foreign currency translation gain (loss)							14,000			14,000
Net loss						(1,910,000)			(126,000)	(2,036,000)
Balance (in shares) at Mar. 31, 2022				12,829,877
Balance at Mar. 31, 2022				$ 13,000	$ 258,614,000	$ (256,833,000)	$ 45,000		$ (557,000)	$ 1,282,000
[1]	Accumulated other comprehensive loss.

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Cash flows from operating activities:
Net loss	$ (2,036,000)	$ (2,531,000)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	150,000	166,000
Stock-based compensation expense	42,000	258,000
Amortization of Debt Discount (Premium)	213,000	908,000
Reserve for excess and slow-moving inventories	374,000	(4,000)
Gain on extinguishment of debt		(652,000)
Net change in operating assets and liabilities:
Accounts receivable	(1,442,000)	556,000
Inventories	(383,000)	(718,000)
Prepaid expenses and other assets	103,000	148,000
Accounts payable	599,000	(38,000)
Interest payable – related party	(2,078,000)	(1,532,000)
Accrued payroll and related expenses	107,000	124,000
Deferred revenue – short term	441,000	88,000
Other current liabilities	(112,000)	(603,000)
Long-term deferred revenue and other noncurrent liabilities	(137,000)	(122,000)
Net cash used in operating activities	(4,159,000)	(3,952,000)
Cash flows from investing activities:
Capital expenditures	(65,000)	(27,000)
Net cash used in investing activities	(65,000)	(27,000)
Cash flows from financing activities:
Proceeds from issuance of common stock, net of $87,000 in expenses	594,000	6,832,000
Net cash provided by financing activities	594,000	6,832,000
Effects of foreign currency rate changes on cash and cash equivalents	2,000
Net increase (decrease) in cash and cash equivalents	(3,628,000)	2,853,000
Cash and cash equivalents at beginning of period	7,280,000	7,161,000
Cash and cash equivalents at end of period	3,652,000	10,014,000
Supplemental disclosures of cash flow information:
Cash paid for related party interest	2,628,000	2,082,000
Cash paid for interest	60,000	$ 60,000
Related party convertible note price reset	$ 213,000

Note 1 - Description of Busines

Note 1 - Description of Business	3 Months Ended
	Mar. 31, 2022
Notes to Financial Statements
Business Description and Basis of Presentation [Text Block]	1. The Company develops and commercializes a range of automated technologies for cell-banking, cell-processing, and cell-based therapeutics. Since the 1990’s 1986 Medical Device Products for Automated Cell Processing The Company provides the AutoXpress® and BioArchive® platforms for automated clinical bio-banking, PXP® platform for point-of-care cell-based therapies and CAR-TXpress™ platform for large scale cell manufacturing services. All product lines are reporting as a single reporting segment in the financial statements.

Note 2 - Going Concern

Note 2 - Going Concern	3 Months Ended
	Mar. 31, 2022
Notes to Financial Statements
Substantial Doubt about Going Concern [Text Block]	2. At March 31, 2022, may may one The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern. The consolidated financial statements do not may

Note 3 - Summary of Significant

Note 3 - Summary of Significant Accounting Policies	3 Months Ended
	Mar. 31, 2022
Notes to Financial Statements
Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block]	3. There have been no 2021 Basis of Presentation The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (U.S. GAAP) for interim financial information and with the instructions to Form 10 8 X. Operating results for the three March 31, 2022 not may December 31, 2022. 10 December 31, 2021. Principles of Consolidation The consolidated financial statements include the accounts of ThermoGenesis Holdings and its wholly-owned subsidiaries, ThermoGenesis Corp. and TotipotentRX Cell Therapy, Pvt. Ltd and ThermoGenesis Corp’s majority-owned subsidiary, CARTXpress Bio. All significant intercompany accounts and transactions have been eliminated upon consolidation. The 20% ownership interest of CARTXpress Bio that is not Recently Adopted Accounting Standards On January 1, 2022, 2020 06 Debt-Debt with Conversion and Other Options ( Subtopic 470 20 ) and Derivatives and Hedging-Contracts in Entity s Own Equity ( Subtopic 815 40 ): Accounting for Convertible Instruments and Contracts in an Entity s Own Equity, 2020 06 1 2 3 January 1, 2022

Note 4 - Related Party Transact

Note 4 - Related Party Transactions	3 Months Ended
	Mar. 31, 2022
Notes to Financial Statements
Related Party Transactions Disclosure [Text Block]	4. Convertible Promissory Note and Revolving Credit Agreement In March 2017, March 6, 2022 ( December 31, 2021, March 4, 2022, one March 6, 2023. The Credit Agreement and the Convertible Promissory Note issued thereunder (as amended, the “Note”) provide that the principal and all accrued and unpaid interest under the Loan will be due and payable on the Maturity Date, with payments of interest-only due on the last day of each calendar year. The Loan bears interest at 22% per annum, simple interest. The Company has five The following summarizes the Note: Maturity Date Stated Interest Rate Conversion Price Carrying Value At March 31, 2022 3/6/2023 22 % $ 0.64 $ 10,000,000 At December 31, 2021 3/6/2022 22 % $ 1.80 $ 9,245,000 The Note includes a down round provision that lowers its conversion price if the Company sells shares of common stock at a lower price per share. In February 2022, $213,000 Before After Conversion Price $ 1.80 $ 0.64 Term (in years) 0.02 0.02 Volatility 39.53 % 39.53 % Dividend rate 0 % 0 % Risk free rate 1.97 % 1.97 % The Company amortized $213,000 three March 31, 2022 2021, March 31, 2022 2021. March 31, 2022 December 31, 2021 On March 4, 2022, one March 6, 2023. No no March 31, 2022 Boyalife Genomics On March 24, 2022, Under the terms of the agreement, the Company transferred its remaining 8.64% interest in ImmuneCyte to Boyalife Genomics and agreed to pay a running royalty of 7.5% of its annual net sales of products and services that are covered by one March 31, 2022, Z3 Also on March 24, 2022, five Z3 April 1, 2022, first six

Note 5 - Convertible Promissory

Note 5 - Convertible Promissory Note	3 Months Ended
	Mar. 31, 2022
Notes to Financial Statements
Debt Disclosure [Text Block]	5. July 2019 On July 23, 2019, “July 2019 July 2019 July 2019 twenty-four July 2019 three July 31, 2022. The following summarizes the July 2019 Maturity Date Stated Interest Rate Conversion Price Carrying Value At March 31, 2022 7/31/2022 24 % $ 0.61 $ 1,000,000 At December 31, 2021 7/31/2022 24 % $ 0.91 $ 813,000 Amortization of debt discount on the July 2019 $0 three March 31, 2022 2021, July 2019 March 31, 2022 2021.

Note 6 - Stockholders' Equity

Note 6 - Stockholders' Equity	3 Months Ended
	Mar. 31, 2022
Notes to Financial Statements
Share-Based Payment Arrangement [Text Block]	6. Equity Common Stock On February 3, 2022, No. 2 may No. 2 August 9, 2022 Equity Plans On January 13, 2022, 2016 may Net Loss Per Share Net loss per share is computed by dividing the net loss by the weighted average number of common shares outstanding. The calculation of the basic and diluted earnings per share is the same for all periods presented, as the effect of the potential common stock equivalents noted below is anti-dilutive due to the Company’s net loss position for all periods presented. Anti-dilutive securities consisted of the following at March 31: 2022 2021 Common stock equivalents of convertible promissory note and accrued interest 17,420,222 6,449,950 Warrants – other 653,248 653,248 Stock options 342,670 889,636 Total 18,416,140 7,992,834

Note 7 - Revenue

Note 7 - Revenue	3 Months Ended
	Mar. 31, 2022
Notes to Financial Statements
Revenue from Contract with Customer [Text Block]	7. The following table summarizes the revenues by product line and type: Three Months Ended March 31, 2022 Device Revenue Service Revenue Other Revenue Total Revenue AXP $ 1,711,000 $ 55,000 $ -- $ 1,766,000 BioArchive 155,000 298,000 -- 453,000 CAR-TXpress 199,000 43,000 71,000 313,000 Manual Disposables 105,000 -- -- 105,000 Other 17,000 -- 9,000 26,000 Total $ 2,187,000 $ 396,000 $ 80,000 $ 2,663,000 Three Months Ended March 31, 2021 Device Revenue Service Revenue Other Revenue Total Revenue AXP $ 225,000 $ 39,000 $ -- $ 264,000 BioArchive 208,000 542,000 -- 750,000 CAR-TXpress 255,000 28,000 71,000 354,000 Manual Disposables 129,000 -- -- 129,000 Other 7,000 -- 13,000 20,000 Total $ 824,000 $ 609,000 $ 84,000 $ 1,517,000 Contract Balances Generally, all sales are contract sales (with either an underlying contract or purchase order). The Company does not three March 31, 2022 March 31, 2022 December 31, 2021, March 31, 2022 December 31, 2021, Backlog of Remaining Customer Performance Obligations The following table represents revenue expected to be recognized in the future from the backlog of performance obligations that are unsatisfied (or partially unsatisfied) at the end of the reporting period: Remainder of 2022 2023 2024 2025 2026 and beyond Total Service revenue $ 1,075,000 $ 666,000 $ 184,000 $ 83,000 $ -- $ 2,008,000 Device revenue (1) 712,000 733,000 41,000 -- -- 1,486,000 Exclusivity fee 214,000 286,000 286,000 286,000 190,000 1,262,000 Other 10,000 13,000 13,000 13,000 140,000 189,000 Total $ 2,011,000 $ 1,698,000 $ 524,000 $ 382,000 $ 330,000 $ 4,945,000 ( 1 Represents the minimum purchase requirements under the distribution agreement the Company signed with its AXP distributor in China.

Note 8 - Concentrations

Note 8 - Concentrations	3 Months Ended
	Mar. 31, 2022
Notes to Financial Statements
Concentration Risk Disclosure [Text Block]	8. The Company had certain customers whose revenue individually represented 10% 10% Accounts Receivable March 31, 2022 December 31, 2021 Customer 1 35 % -- Customer 2 16 % -- Customer 3 1 % 23 % Customer 4 9 % 23 % Three Months Ended March 31, Revenues 2022 2021 Customer 1 $ 1,271,000 48 % $ 151,000 10 % Customer 2 $ 2,000 -- $ 316,000 21 %

Note 9 - Subsequent Events

Note 9 - Subsequent Events	3 Months Ended
	Mar. 31, 2022
Notes to Financial Statements
Subsequent Events [Text Block]	9. Subsequent Events Effective April 1, 2022, September 30, 2027.

Significant Accounting Policies

Significant Accounting Policies (Policies)	3 Months Ended
	Mar. 31, 2022
Accounting Policies [Abstract]
Basis of Accounting, Policy [Policy Text Block]	Basis of Presentation The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (U.S. GAAP) for interim financial information and with the instructions to Form 10 8 X. Operating results for the three March 31, 2022 not may December 31, 2022. 10 December 31, 2021.
Consolidation, Policy [Policy Text Block]	Principles of Consolidation The consolidated financial statements include the accounts of ThermoGenesis Holdings and its wholly-owned subsidiaries, ThermoGenesis Corp. and TotipotentRX Cell Therapy, Pvt. Ltd and ThermoGenesis Corp’s majority-owned subsidiary, CARTXpress Bio. All significant intercompany accounts and transactions have been eliminated upon consolidation. The 20% ownership interest of CARTXpress Bio that is not
New Accounting Pronouncements, Policy [Policy Text Block]	Recently Adopted Accounting Standards On January 1, 2022, 2020 06 Debt-Debt with Conversion and Other Options ( Subtopic 470 20 ) and Derivatives and Hedging-Contracts in Entity s Own Equity ( Subtopic 815 40 ): Accounting for Convertible Instruments and Contracts in an Entity s Own Equity, 2020 06 1 2 3 January 1, 2022

Note 4 - Related Party Transa_2

Note 4 - Related Party Transactions (Tables)	3 Months Ended
	Mar. 31, 2022
Notes Tables
Schedule of Related Party Transactions [Table Text Block]	Maturity Date Stated Interest Rate Conversion Price Carrying Value At March 31, 2022 3/6/2023 22 % $ 0.64 $ 10,000,000 At December 31, 2021 3/6/2022 22 % $ 1.80 $ 9,245,000
Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]	Before After Conversion Price $ 1.80 $ 0.64 Term (in years) 0.02 0.02 Volatility 39.53 % 39.53 % Dividend rate 0 % 0 % Risk free rate 1.97 % 1.97 %

Note 5 - Convertible Promisso_2

Note 5 - Convertible Promissory Note (Tables)	3 Months Ended
	Mar. 31, 2022
Notes Tables
Convertible Debt [Table Text Block]	Maturity Date Stated Interest Rate Conversion Price Carrying Value At March 31, 2022 7/31/2022 24 % $ 0.61 $ 1,000,000 At December 31, 2021 7/31/2022 24 % $ 0.91 $ 813,000

Note 6 - Stockholders' Equity (

Note 6 - Stockholders' Equity (Tables)	3 Months Ended
	Mar. 31, 2022
Notes Tables
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]	2022 2021 Common stock equivalents of convertible promissory note and accrued interest 17,420,222 6,449,950 Warrants – other 653,248 653,248 Stock options 342,670 889,636 Total 18,416,140 7,992,834

Note 7 - Revenue (Tables)

Note 7 - Revenue (Tables)	3 Months Ended
	Mar. 31, 2022
Notes Tables
Disaggregation of Revenue [Table Text Block]	Three Months Ended March 31, 2022 Device Revenue Service Revenue Other Revenue Total Revenue AXP $ 1,711,000 $ 55,000 $ -- $ 1,766,000 BioArchive 155,000 298,000 -- 453,000 CAR-TXpress 199,000 43,000 71,000 313,000 Manual Disposables 105,000 -- -- 105,000 Other 17,000 -- 9,000 26,000 Total $ 2,187,000 $ 396,000 $ 80,000 $ 2,663,000 Three Months Ended March 31, 2021 Device Revenue Service Revenue Other Revenue Total Revenue AXP $ 225,000 $ 39,000 $ -- $ 264,000 BioArchive 208,000 542,000 -- 750,000 CAR-TXpress 255,000 28,000 71,000 354,000 Manual Disposables 129,000 -- -- 129,000 Other 7,000 -- 13,000 20,000 Total $ 824,000 $ 609,000 $ 84,000 $ 1,517,000
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Table Text Block]	Remainder of 2022 2023 2024 2025 2026 and beyond Total Service revenue $ 1,075,000 $ 666,000 $ 184,000 $ 83,000 $ -- $ 2,008,000 Device revenue (1) 712,000 733,000 41,000 -- -- 1,486,000 Exclusivity fee 214,000 286,000 286,000 286,000 190,000 1,262,000 Other 10,000 13,000 13,000 13,000 140,000 189,000 Total $ 2,011,000 $ 1,698,000 $ 524,000 $ 382,000 $ 330,000 $ 4,945,000

Note 8 - Concentrations (Tables

Note 8 - Concentrations (Tables)	3 Months Ended
	Mar. 31, 2022
Notes Tables
Schedules of Concentration of Risk, by Risk Factor [Table Text Block]	Accounts Receivable March 31, 2022 December 31, 2021 Customer 1 35 % -- Customer 2 16 % -- Customer 3 1 % 23 % Customer 4 9 % 23 % Three Months Ended March 31, Revenues 2022 2021 Customer 1 $ 1,271,000 48 % $ 151,000 10 % Customer 2 $ 2,000 -- $ 316,000 21 %

Note 2 - Going Concern (Details

Note 2 - Going Concern (Details Textual) - USD ($)	Mar. 31, 2022	Dec. 31, 2021
Cash and Cash Equivalents, at Carrying Value, Total	$ 3,652,000	$ 7,280,000
Working Capital	$ 2,283,000

Note 3 - Summary of Significa_2

Note 3 - Summary of Significant Accounting Policies (Details Textual) - USD ($)	Mar. 31, 2022	Jan. 01, 2022
Cumulative Effect of Applying Accounting Standards Update on Accumulated Deficit		$ 9,739,000
Reduction of Additional Paid In Capital Due to Recombination		10,681,000
Reduction of Debt Discounts of Convertible Promissory Notes		$ 942,000
CAR-TXpress [Member]
Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners	20.00%
Noncontrolling Interest, Ownership Percentage by Parent	80.00%

Note 4 - Related Party Transa_3

Note 4 - Related Party Transactions (Details Textual)	3 Months Ended
	Mar. 31, 2022USD ($)$ / shares	Mar. 31, 2021USD ($)	Mar. 24, 2022USD ($)ft²	Mar. 04, 2022USD ($)	Dec. 31, 2021USD ($)	Mar. 31, 2017USD ($)
Amortization of Debt Discount (Premium)	$ 213,000	$ 908,000
Interest Paid, Excluding Capitalized Interest, Operating Activities	60,000	60,000
Notes Payable, Related Parties, Current	10,000,000
Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Total	14,000	1,000
Boyalife Asset Holding II [Member]
Royalty Expense	0
Lease Agreement with Z3 Investment LLC [Member]
Lessee, Operating Lease, Term of Contract (Year)			5 years
Area of Real Estate Property (Square Foot) | ft²			35,475
First Six Months, Rental Expense, Operating Leases			$ 46,000
Second Six Months, Rental Expense, Operating Lease			$ 104,000
Percent Increase, Annual Rental Expense			4.00%
ImmuneCyte [Member]
Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Total	$ 8.64
Royalty, Percent of Annual Net Sales, US Patents			7.50%
Royalty, Percent of Annual Net Sales, Other Licensed Intellectual Property			5.00%
Boyalife Asset Holding II [Member] | Revolving Credit Facility [Member]
Line of Credit Facility, Maximum Borrowing Capacity						$ 10,000,000
Long-term Line of Credit, Total					$ 10,000,000
Debt Instrument, Interest Rate, Stated Percentage	22.00%
Debt Instrument, Convertible, Conversion Price (in dollars per share) | $ / shares	$ 0.64
Amortization of Debt Discount (Premium)	$ 213,000	827,000
Interest Paid, Excluding Capitalized Interest, Operating Activities	550,000	$ 550,000
Interest Payable	$ 153,000				$ 2,231,000
Notes Payable, Related Parties, Current				$ 10,000,000

Note 4 - Related Party Transa_4

Note 4 - Related Party Transactions - Summarizes the Note (Details) - Boyalife Asset Holding II [Member] - Convertible Debt [Member] - USD ($)	Mar. 31, 2022	Dec. 31, 2021
State interest rate	22.00%	22.00%
Conversion price (in dollars per share)	$ 0.64	$ 1.80
Face value	$ 10,000,000	$ 9,245,000

Note 4 - Related Party Transa_5

Note 4 - Related Party Transactions - Black-Scholes Pricing Model (Details)	Feb. 26, 2022	Feb. 25, 2022
Measurement Input, Conversion Price [Member]
Measurement input	0.64	1.80
Measurement Input, Expected Term [Member]
Measurement input	0.02	0.02
Measurement Input, Price Volatility [Member]
Measurement input	0.3953	0.3953
Measurement Input, Expected Dividend Rate [Member]
Measurement input	0	0
Measurement Input, Risk Free Interest Rate [Member]
Measurement input	0.0197	0.0197

Note 5 - Convertible Promisso_3

Note 5 - Convertible Promissory Note (Details Textual) - USD ($)	Jul. 23, 2019	Mar. 31, 2022	Mar. 31, 2021	Dec. 31, 2021
Amortization of Debt Discount (Premium)		$ 213,000	$ 908,000
Convertible Debt [Member] | The July 2019 Note [Member]
Debt Instrument, Face Amount	$ 1,000,000
Debt Instrument, Convertible, Conversion Price (in dollars per share)		$ 0.61		$ 0.91
Debt Instrument, Convertible, Threshold Percentage of Stock Price Trigger	90.00%
Debt Instrument, Interest Rate, Stated Percentage	24.00%	24.00%		24.00%
Amortization of Debt Discount (Premium)		$ 0	80,000
Interest Expense, Debt, Total		$ 60,000	$ 60,000
Convertible Debt [Member] | The July 2019 Note [Member] | Maximum [Member]
Debt Instrument, Convertible, Conversion Price (in dollars per share)	$ 1.80
Convertible Debt [Member] | The July 2019 Note [Member] | Minimum [Member]
Debt Instrument, Convertible, Conversion Price (in dollars per share)	$ 0.50

Note 5 - Convertible Promisso_4

Note 5 - Convertible Promissory Note - Convertible Promissory Note (Details) - Convertible Debt [Member] - The July 2019 Note [Member] - USD ($)	3 Months Ended	12 Months Ended
	Mar. 31, 2022	Dec. 31, 2021	Jul. 23, 2019
Maturity Date	Jul. 31, 2022	Jul. 31, 2022
Stated Interest Rate	24.00%	24.00%	24.00%
Conversion Price (in dollars per share)	$ 0.61	$ 0.91
Carrying Value	$ 1,000,000	$ 813,000

Note 6 - Stockholders' Equity_2

Note 6 - Stockholders' Equity (Details Textual) - USD ($)	Jan. 13, 2022	Mar. 31, 2022	Mar. 31, 2022	Mar. 31, 2021	Feb. 03, 2022
Proceeds from Issuance of Common Stock, Net			$ 594,000	$ 6,832,000
The 2016 Plan [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized (in shares)	392,500
Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized (in shares)	1,200,000
At The Market Offering Agreement [Member]
Additional Common Stock, Shares Authorized					$ 4,275,000
Stock Issued During Period, Shares, New Issues (in shares)		918,093
Proceeds from Issuance of Common Stock		$ 681,000
Shares Issued, Average Price Per Share (in dollars per share)		$ 0.74
Proceeds from Issuance of Common Stock, Net		$ 594,000
Payments of Stock Issuance Costs		$ 87,000
Minimum [Member] | At The Market Offering Agreement [Member]
Maximum Offering Price for Issuance of Common Stock					15,280,313
Maximum [Member] | At The Market Offering Agreement [Member]
Maximum Offering Price for Issuance of Common Stock					$ 19,555,261

Note 6 - Stockholders' Equity -

Note 6 - Stockholders' Equity - Anti-dilutive Securities (Details) - shares	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Anti-dilutive securities (in shares)	18,416,140	7,992,834
Convertible Debt Securities [Member]
Anti-dilutive securities (in shares)	17,420,222	6,449,950
Warrant, Other [Member]
Anti-dilutive securities (in shares)	653,248	653,248
Share-Based Payment Arrangement, Option [Member]
Anti-dilutive securities (in shares)	342,670	889,636

Note 7 - Revenue (Details Textu

Note 7 - Revenue (Details Textual) - USD ($)	3 Months Ended
	Mar. 31, 2022	Dec. 31, 2021
Contract with Customer, Liability, Revenue Recognized	$ 446,000
Contract with Customer, Liability, Current	1,159,000	$ 719,000
Contract with Customer, Liability, Noncurrent	$ 1,163,000	$ 1,244,000

Note 7 - Revenue - Revenues (De

Note 7 - Revenue - Revenues (Details) - USD ($)	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Revenues	$ 2,663,000	$ 1,517,000
Device [Member] | AXP [Member]
Revenues	1,766,000	264,000
Device [Member] | BioArchive [Member]
Revenues	453,000	750,000
Device [Member] | CAR-TXpress [Member]
Revenues	313,000	354,000
Device [Member] | Manual Disposables [Member]
Revenues	105,000	129,000
Device [Member] | Other Subsegments [Member]
Revenues	26,000	20,000
Device Revenue [Member]
Revenues	2,187,000	824,000
Device Revenue [Member] | Device [Member] | AXP [Member]
Revenues	1,711,000	225,000
Device Revenue [Member] | Device [Member] | BioArchive [Member]
Revenues	155,000	208,000
Device Revenue [Member] | Device [Member] | CAR-TXpress [Member]
Revenues	199,000	255,000
Device Revenue [Member] | Device [Member] | Manual Disposables [Member]
Revenues	105,000	129,000
Device Revenue [Member] | Device [Member] | Other Subsegments [Member]
Revenues	17,000	7,000
Service [Member]
Revenues	396,000	609,000
Service [Member] | Device [Member] | AXP [Member]
Revenues	55,000	39,000
Service [Member] | Device [Member] | BioArchive [Member]
Revenues	298,000	542,000
Service [Member] | Device [Member] | CAR-TXpress [Member]
Revenues	43,000	28,000
Other [Member]
Revenues	80,000	84,000
Other [Member] | Device [Member] | CAR-TXpress [Member]
Revenues	71,000	71,000
Other [Member] | Device [Member] | Other Subsegments [Member]
Revenues	$ 9,000	$ 13,000

Note 7 - Revenue - Remaining Pe

Note 7 - Revenue - Remaining Performance Obligations (Details)	Mar. 31, 2022USD ($)
Revenue, Remaining Performance Obligation, Amount	$ 4,945,000
Service [Member]
Revenue, Remaining Performance Obligation, Amount	2,008,000
Device Revenue [Member]
Revenue, Remaining Performance Obligation, Amount	1,486,000	[1]
Exclusivity Fee [Member]
Revenue, Remaining Performance Obligation, Amount	1,262,000
Product and Service, Other [Member]
Revenue, Remaining Performance Obligation, Amount	$ 189,000
[1]	Represents the minimum purchase requirements under the distribution agreement the Company signed with its AXP distributor in China.

Note 7 - Revenue - Remaining _2

Note 7 - Revenue - Remaining Performance Obligations 2 (Details)	Mar. 31, 2022USD ($)
Revenue, Remaining Performance Obligation, Amount	$ 4,945,000
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2022-04-01
Revenue, Remaining Performance Obligation, Amount	$ 2,011,000
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction (Year)	9 months
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2023-01-01
Revenue, Remaining Performance Obligation, Amount	$ 1,698,000
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction (Year)	1 year
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2024-01-01
Revenue, Remaining Performance Obligation, Amount	$ 524,000
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction (Year)	1 year
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2025-01-01
Revenue, Remaining Performance Obligation, Amount	$ 382,000
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction (Year)	1 year
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2026-01-01
Revenue, Remaining Performance Obligation, Amount	$ 330,000
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction (Year)	1 year
Service [Member]
Revenue, Remaining Performance Obligation, Amount	$ 2,008,000
Service [Member] | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2022-04-01
Revenue, Remaining Performance Obligation, Amount	$ 1,075,000
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction (Year)	9 months
Service [Member] | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2023-01-01
Revenue, Remaining Performance Obligation, Amount	$ 666,000
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction (Year)	1 year
Service [Member] | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2024-01-01
Revenue, Remaining Performance Obligation, Amount	$ 184,000
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction (Year)	1 year
Service [Member] | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2025-01-01
Revenue, Remaining Performance Obligation, Amount	$ 83,000
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction (Year)	1 year
Device Revenue [Member]
Revenue, Remaining Performance Obligation, Amount	$ 1,486,000	[1]
Device Revenue [Member] | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2022-04-01
Revenue, Remaining Performance Obligation, Amount	$ 712,000	[1]
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction (Year)	9 months	[1]
Device Revenue [Member] | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2023-01-01
Revenue, Remaining Performance Obligation, Amount	$ 733,000	[1]
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction (Year)	1 year	[1]
Device Revenue [Member] | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2024-01-01
Revenue, Remaining Performance Obligation, Amount	$ 41,000	[1]
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction (Year)	1 year	[1]
Exclusivity Fee [Member]
Revenue, Remaining Performance Obligation, Amount	$ 1,262,000
Exclusivity Fee [Member] | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2022-04-01
Revenue, Remaining Performance Obligation, Amount	$ 214,000
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction (Year)	9 months
Exclusivity Fee [Member] | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2023-01-01
Revenue, Remaining Performance Obligation, Amount	$ 286,000
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction (Year)	1 year
Exclusivity Fee [Member] | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2024-01-01
Revenue, Remaining Performance Obligation, Amount	$ 286,000
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction (Year)	1 year
Exclusivity Fee [Member] | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2025-01-01
Revenue, Remaining Performance Obligation, Amount	$ 286,000
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction (Year)	1 year
Exclusivity Fee [Member] | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2026-01-01
Revenue, Remaining Performance Obligation, Amount	$ 190,000
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction (Year)	1 year
Product and Service, Other [Member]
Revenue, Remaining Performance Obligation, Amount	$ 189,000
Product and Service, Other [Member] | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2022-04-01
Revenue, Remaining Performance Obligation, Amount	$ 10,000
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction (Year)	9 months
Product and Service, Other [Member] | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2023-01-01
Revenue, Remaining Performance Obligation, Amount	$ 13,000
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction (Year)	1 year
Product and Service, Other [Member] | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2024-01-01
Revenue, Remaining Performance Obligation, Amount	$ 13,000
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction (Year)	1 year
Product and Service, Other [Member] | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2025-01-01
Revenue, Remaining Performance Obligation, Amount	$ 13,000
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction (Year)	1 year
Product and Service, Other [Member] | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2026-01-01
Revenue, Remaining Performance Obligation, Amount	$ 140,000
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction (Year)	1 year
[1]	Represents the minimum purchase requirements under the distribution agreement the Company signed with its AXP distributor in China.

Note 8 - Concentrations - Accou

Note 8 - Concentrations - Accounts Receivables and Revenues (Details) - USD ($)	3 Months Ended		12 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Dec. 31, 2021
Revenues	$ 2,663,000	$ 1,517,000
Customer 1 [Member]
Revenues	1,271,000	151,000
Customer 2 [Member]
Revenues	$ 2,000	$ 316,000
Accounts Receivable [Member] | Customer Concentration Risk [Member] | Customer 1 [Member]
Accounts receivable, percent	35.00%
Accounts receivable, percent	35.00%
Accounts Receivable [Member] | Customer Concentration Risk [Member] | Customer 2 [Member]
Accounts receivable, percent	16.00%
Accounts receivable, percent	16.00%
Accounts Receivable [Member] | Customer Concentration Risk [Member] | Customer 3 [Member]
Accounts receivable, percent	1.00%		23.00%
Accounts receivable, percent	1.00%		23.00%
Accounts Receivable [Member] | Customer Concentration Risk [Member] | Customer 4 [Member]
Accounts receivable, percent	9.00%		23.00%
Accounts receivable, percent	9.00%		23.00%
Revenue Benchmark [Member] | Customer Concentration Risk [Member] | Customer 1 [Member]
Accounts receivable, percent	48.00%	10.00%
Accounts receivable, percent	48.00%	10.00%
Revenue Benchmark [Member] | Customer Concentration Risk [Member] | Customer 2 [Member]
Accounts receivable, percent		21.00%
Accounts receivable, percent		21.00%

Note 9 - Subsequent Events (Det

Note 9 - Subsequent Events (Details Textual)	Apr. 01, 2022ft²
Subsequent Event [Member] | Laboratory, Office, and Manufacturing Facility in Rancho Cordova, California [Member]
Area of Real Estate Property (Square Foot)	35,745